Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Veena Shankaran receives the Lert Family Endowed Chair at Fred Hutch

Veena Shankaran, co-director of the Hutchinson Institute for Cancer Outcomes Research at Fred Hutch Cancer Center,was awarded the newly established Lert Family Endowed Chair. A gastrointestinal cancer specialist, she is also a professor at Fred Hutch and UW Medicine.

June 18, 2026

Vol.52 No.24

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.

June 05, 2026

Vol.52 No.22

By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Clinical Roundup

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

June 05, 2026

Vol.52 No.22

Cancer Policy

FDA advisory panel votes to recommend updated 2026-2027 formula for COVID-19 vaccines

The Vaccines and Related Biological Products Advisory Committee on May 28 approved the composition of COVID-19 vaccines for the 2026-2027 immunization season.

May 29, 2026

Vol.52 No.21

By Claire Marie Porter

Cancer Policy

HHS rescinds vaccine panel charter citing “administrative error”

The charter governing the Advisory Committee on Immunization Practices will be returned to its previous framework for two years because the Department of Health and Human Services didn’t allow sufficient time for public comment after Robert F. Kennedy crafted a charter more favorable to his policy preferences.

May 22, 2026

Vol.52 No.20

By Claire Marie Porter

Clinical Roundup

Intismeran cancer vaccine + Keytruda sustains 49% melanoma reduction after five years

A combination of a cancer vaccine and a drug, both of which harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence and death by 49%, according to a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center.

May 22, 2026

Vol.52 No.20

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

YOU MAY BE INTERESTED IN

Veena Shankaran receives the Lert Family Endowed Chair at Fred Hutch

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

FDA advisory panel votes to recommend updated 2026-2027 formula for COVID-19 vaccines

HHS rescinds vaccine panel charter citing “administrative error”

Intismeran cancer vaccine + Keytruda sustains 49% melanoma reduction after five years

Renew today!

Subscriber content

Never miss an issue!

Login